Acadia Pharma (ACAD) Tops Q3 EPS by 17c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 8, 2021 4:05 PM EST- 3Q21 net sales of $131.6 million, a 9% increase over 3Q20
- FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2021.
Our third-quarter results reflect volume growth across all channels and our strong relative performance underscores our commercial teams ability to drive sales of NUPLAZID in a challenging environment, said Steve Davis, Chief Executive Officer. As we... More
